KR20030079185A - Processing method and its Application of Medicine for Treating Mastitis of Expectant and Dairycow Using Dandelion Extract - Google Patents
Processing method and its Application of Medicine for Treating Mastitis of Expectant and Dairycow Using Dandelion Extract Download PDFInfo
- Publication number
- KR20030079185A KR20030079185A KR1020020018031A KR20020018031A KR20030079185A KR 20030079185 A KR20030079185 A KR 20030079185A KR 1020020018031 A KR1020020018031 A KR 1020020018031A KR 20020018031 A KR20020018031 A KR 20020018031A KR 20030079185 A KR20030079185 A KR 20030079185A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- mastitis
- treatment
- tincture
- tinture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 수의학과 의학에 관계되는 더 구체적으로는 동물과 인체의 유방염 치료에 새로운 조제약 생산 방법에 관련되며 이것은 인간의 유방염 치료의 의학적 실시뿐 아니라 모든 종류의 동물의 다양한 유방염의 수의학적 치료에 이용된다.The present invention relates more specifically to veterinary medicine and more specifically to methods of producing new pharmaceuticals for the treatment of mastitis in animals and humans, which are used not only for the medical practice of treating mastitis in humans but also for the veterinary treatment of various mastitis in all kinds of animals. do.
본 발명은 유방염 치료에 있어서 매우 효과적이고, 독성이 없고 부작용이 없는 신규 조제약의 생산방법의 제공에 기초된다.The present invention is based on the provision of a method for producing a novel pharmaceutical which is very effective in treating mastitis, is non-toxic and has no side effects.
동물과 인간의 유방염 치료를 위한 다양한 화학제약학적 약품의 생산방법은 공지된 기술이다. 이들 대부분의 약품은 항생제들로 그중 가장 많이 사용되는 것은 페니실린과 스트렙토마이신이다(81%).Methods of producing various chemical pharmaceuticals for the treatment of mastitis in animals and humans are known techniques. Most of these drugs are the most commonly used antibiotics, with penicillin and streptomycin (81%).
이러한 항생제들이 동물의 유방염 치료시에 오일베이스, 페레디니졸, 거품형성제 그리고 촉진제와 결합된 다양한 조성물 제조 방법은 잘 알려져 있다. 이들 조성물들은 시발원소에 혼합되어 제조된다. 그러나 조성물들의 이용성은 충분치 않다. 항생제로 제조된 약품으로 유방염의 치료는 부작용과 위장기관의 기능에 질병과 몸의 병에 대한 저항성이 낮아지는 원인이 된다. 본 발명은 국화과에 속하는 포공영으로 부터 항균활성이 높은 엑기스를 추출, 정제하여 임산부와 젖소의 유방염 또는 유방염을 치료하는 발명이다.Methods of preparing various compositions in which these antibiotics are combined with oil bases, peredinisols, foaming agents and accelerators in the treatment of mastitis in animals are well known. These compositions are prepared by mixing in the starting element. However, the availability of the compositions is not sufficient. Antibiotic drugs are used to treat mastitis, which can cause side effects and lower gastrointestinal function. The present invention is an invention for treating mastitis or mastitis of pregnant women and cows by extracting and purifying extracts with high antibacterial activity from pogongyoung belonging to the Asteraceae.
일반적으로 포공영은 국화과 식물의 전초로서 그 주요 성분으로는 타락사신(Taraxacin), 타락사롤 (Taraxarol), 타락사코사이드(Taraxacoside), 여러 지방산, 이눌린(Inulin), 베타-시토스테롤(β- Sitosterol), 베타-아미린(β-Amyrin) 등이 알려져 있다.In general, pogongyoung is an outpost of asteraceae, its main components are Taraxacin (Taraxacin), Taraxalol (Taraxarol), Taraxaccoside, various fatty acids, Inulin, β-Sitosterol, Β-Amyrin and the like are known.
이러한 포공영을 탕제로 사용할 경우 동의보감, 중약대사전 등에 나타난 한의학적 약리작용으로는 청열해독, 이담, 이뇨, 급성유방염, 결막염, 기관지염 등의 염증치료, 항진균 효과, 건위작용, 항균효과가 있는 것으로 알려져 있다.The use of pogongyoung as a medicinal herb is known to have medicinal pharmacological effects such as synergism, medicinal metabolism, etc., including antipyretic detoxification, edema, diuresis, acute mastitis, conjunctivitis, bronchitis, antifungal effect, palliative action, and antibacterial effect.
또한 포공영은 현대의학에서 수용성 추출물을 분리, 정제하여 이뇨제로 이용되고 있으며, 인체에 대한 독성이 없어 전초를 동결건조 후 분말화 시켜 건강식품으로 판매하고 있다.In addition, Pogongyoung is used as a diuretic by separating and purifying water-soluble extracts in modern medicine, and since it is not toxic to humans, it is powdered and then sold as health food.
한편, 포공영의 항균작용에 대한 연구는 아직 발표된 것이 없으며 현재까지의 주된 연구는 그 함유성분에 관한 것으로써 R. Aexel과 S. Evans 등에 의한 트리터펜(Triterpen)계 화합물, H. Nitsche 등에 의한 네옥산틴(Neoxanthin), Hans-WilliRauwald 등에 의한 타락사코사이드(Taraxacoside) 등이 있다.On the other hand, no research on the antimicrobial activity of pogongyoung has been published yet, and the main studies to date have been made on the components thereof, by Triterpene compounds by R. Aexel and S. Evans, H. Nitsche, etc. Nexaanthin, Taraxacoside by Hans-WilliRauwald and the like.
이에 본 발명자들은 생약인 포공영으로부터 항균활성이 높은 엑기스를 추출, 정제함에 있어서 공업적으로 경제성을 높이기 위하여 물, 에탄올, 에틸아세테이트 등과같은 저렴한 가격의 용매를 이용하였을 뿐만 아니라, 정제과정 중 유기 용매만을 사용하는, 아주 효율적이고 간단한 방법을 개발하였고. 이러한 방법으로 얻어진 엑기스의 in vitro 실험을 통하여 항균 활성도를 입증하고 급성 독성 실험을 통하여 본 엑기스가 인체독성이 없음을 입증하였다.Therefore, the present inventors not only used an inexpensive solvent such as water, ethanol, ethyl acetate, etc. in order to increase the industrial economics in extracting and purifying the extract having high antimicrobial activity from the herbal medicine poongongyoung, only organic solvent during the purification process We have developed a very efficient and simple method to use. The antimicrobial activity was verified through in vitro experiments of the extracts obtained in this way, and the acute toxicity test proved that the extract was not human toxic.
따라서, 본 발명의 목적은 포공영으로부터 인체에 대한 독성이 없는 항균 활성 물질을 추출, 정제함에 있어서, 저렴한 유기용매만을 사용하여 간단하면서도 경제적인 추출 및 정제하는 방법을 제공하는데 그 목적이 있다.Accordingly, an object of the present invention is to provide a simple and economical extraction and purification method using only an inexpensive organic solvent in extracting and purifying antimicrobial active substances which are not toxic to human body from poongongyoung.
첫째, 포공영으로부터 항균활성이 뛰어난 물질을 추출함에 있고,First, in extracting an excellent antimicrobial activity from Poongyoung,
둘째, 추출물을 이용한 젓소와 임산부의 유방염 또는 유선염을 치료함에 있고,Second, in the treatment of mastitis or mastitis of dairy cows and pregnant women using the extract,
셋째, 포공영의 추출방법을 개선함으로써 수율의 극대화, 생산원가의 절감 및 대 량생산 체계 확립Third, by improving the extraction method of Pogongyoung, maximize yield, reduce production cost and establish mass production system.
넷째, 포공영 추출물을 이용한 응용가능성을 제공함을 목적으로 한다.Fourth, to provide an applicability using pogongyoung extract.
인간과 동물의 유방염 치료를 위한 민들레(Taraxacum officinale Web.)을 끓는물 95-100℃에서 넣어 적어도 7시간 담구어 둔후 그다음 추출물을 걸러낸 혼합물을 25-30% 암모니아 수용액에 7내지 10일동안 담구어 둔후 상기 추출액과 동중량의 팅크제(tinture)를 분리하고 전술한 약초 추출액과 팅크제(tinture)를 pH가 적어도 10이 되게 혼합하는 것을 특징으로 하는 인체와 동물의 유선염 치료용 약제 제조방법.Dandelion (Taraxacum officinale Web.) For the treatment of human and animal mastitis is soaked in boiling water at 95-100 ° C for at least 7 hours, and then the extract is filtered and immersed in 25-30% aqueous ammonia solution for 7 to 10 days. After baking, the extract and the tincture of the same weight (tinture) is separated and the above-mentioned herbal extract and tincture (tinture) to a pH of at least 10, characterized in that the method for producing a drug for the treatment of human and animal mastitis.
팅크제(tinture)의 제조방법은 마쇄한 포공영 건조분말 1kg을 추출기에 넣고 여기에 비극성 용매인 에탄올 3∼5ℓ을 가하고 60℃에서 6시간 교반한 후 여과하여 포공영 잔체를 얻는다. 이 잔체를 추출기에 넣고 70∼100%의 저급알콜 3∼5ℓ을 가한다음 50℃에서 6시간 교반, 추출한다. 추출이 끝난 뒤 여과하여 그 여액에 무기염류를 가하여 PH농도를 중성으로 조정한 후 농축한다.In the method of preparing tincture, 1 kg of crushed pogongyoung dry powder is placed in an extractor, and 3-5 L of ethanol, which is a nonpolar solvent, is added thereto, stirred at 60 ° C for 6 hours, and filtered to obtain a pogongong residue. This residue is added to an extractor, 3 to 5 L of 70-100% lower alcohol is added, followed by stirring and extraction at 50 ° C for 6 hours. After extraction, it is filtered and inorganic salts are added to the filtrate to adjust the pH to neutral and then concentrated.
여기에 클로로포름 2∼3ℓ과 증류수 2∼3ℓ을 가하여 층 분리한 수용성 추출액을 얻는다.To this, 2 to 3 L of chloroform and 2 to 3 L of distilled water are added to obtain a water-soluble extract liquid separated in layers.
얻어진 수용성 추출액을 60℃에서 1∼1.5ℓ까지 감압 농축하여 유기용매를 제거한다. 여기에 0.1∼0.2N 무기산을 가하여 PH농도를 3∼5로 조정한다.The resulting aqueous extract was concentrated under reduced pressure to 1 to 1.5 L at 60 ° C to remove the organic solvent. 0.1-0.2N inorganic acid is added to it, and pH concentration is adjusted to 3-5.
이때 PH농도가 3미만이면 유효성분의 변질이 생기는 문제가 있고 5를 넘으면 유효성분중의 일부가 유기용매와의 충 분리시 층 사이에서 석출될 우려가 있다.At this time, if the pH concentration is less than 3, there is a problem in that the active ingredient is deteriorated. If the pH is more than 5, a part of the active ingredient may be precipitated between layers when the organic solvent is separated from the organic solvent.
여기에 에탄올을 1∼1.5ℓ씩 3∼4회 가하여 층 분리하여 유기용매 층을 모은 후 60℃이하에서 감압 농축하여 6∼8g의 엑기스를 얻는다.Ethanol is added 1 to 1.5 liters three to four times, and the layers are separated. The organic solvent layer is collected, and concentrated under reduced pressure at 60 ° C. or lower to obtain 6-8 g of extract.
얻어진 엑기스에 10∼20%의 저급알콜 수용액, 100~200ml을 가하여 녹인 후 탄산칼슘을 가하여 PH농도를 5∼7로 조정한다.10-20% of a lower alcohol aqueous solution and 100-200 ml are added to the obtained extract and dissolved, and calcium carbonate is added to adjust the pH to 5-7.
이때 PH농도가 5미만이면 유효성분들이 유기용매와의 층분리 시 각층으로 확산되는 문제가 있고 7을 넘으면 유효성분중의 일부가 유기용매와의 층분리 시 각 층 사이에 석출될 우려가 있다.At this time, if the PH concentration is less than 5, there is a problem in that the active ingredients are diffused into each layer when the layer is separated from the organic solvent, and if it exceeds 7, some of the active ingredients may be precipitated between the layers when the layer is separated from the organic solvent.
여기에 할로겐화합물 또는 저급케톤 100∼200ml을 가하여 층분리한 후 수용층을 60℃이하에서 감압 농축하여 항균활성이 있는 포공영 엑기스 3.5∼4.5g을 얻는다.100-200 ml of a halogen compound or lower ketone is added thereto, and the layers are separated. The aqueous layer is concentrated under reduced pressure at 60 ° C. or lower to obtain 3.5-4.5 g of pogongyoung extract having antimicrobial activity.
위 과정에서 저급 알콜의 %함량은 l0%미만의 경우 유효성분이 수용층과 유기용매층 사이에서 석출되는 현상이 나타나며, 20%이상의 경우 유효성분이 수용층, 유기용매층 모두에 확산되는 현상이 나타난다. 상기의 정제한 엑기스는 인체 독성이 매우 적기 때문에 피부외용제는 물론 경구용제제에 적합하다.In the above process, when the% content of the lower alcohol is less than 10%, the active ingredient is precipitated between the aqueous layer and the organic solvent layer, and when more than 20%, the active ingredient is diffused in both the aqueous layer and the organic solvent layer. Since the purified extract is very low in human toxicity, it is suitable for external skin preparations as well as oral preparations.
이하 본 발명을 실시 예에 의거 상세히 설명하면 다음과 같으며 본 발명이 실시 예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to the following examples, and the present invention is not limited by the examples.
[실시예 1]Example 1
인간과 동물의 유방염 치료를 위한 민들레(Taraxacum officinale Web.)을 끓는물 95-100℃에서 넣어 적어도 7시간 담구어 둔후 그다음 추출물을 걸러낸 혼합물을 25-30% 암모니아 수용액에 7내지 10일동안 담구어 둔후 상기 추출액과 동중량의 팅크제(tinture)를 분리하고 전술한 약초 추출액과 팅크제(tinture)를 pH가 적어도 10이 되게 혼합하는 것을 특징으로 하는 인체와 동물의 유선염 치료용 약제 제조방법.Dandelion (Taraxacum officinale Web.) For the treatment of human and animal mastitis is soaked in boiling water at 95-100 ° C for at least 7 hours, and then the extract is filtered and immersed in 25-30% aqueous ammonia solution for 7 to 10 days. After baking, the extract and the tincture of the same weight (tinture) is separated and the above-mentioned herbal extract and tincture (tinture) to a pH of at least 10, characterized in that the method for producing a drug for the treatment of human and animal mastitis.
[실시예 2]Example 2
상기 실시예 1에서 얻은 포공영 엑기스에 대한 항균 효과를 다음표 1에 나타내였는바, MIC(Minimum Inhibitory Concentration) 값은 에릭슨(Ericsson)에 의한 (Broth dilution) 방법으로 24시간 배양 후 측정하였다.The antimicrobial effect on the pogongyeong extract obtained in Example 1 is shown in the following Table 1, MIC (Minimum Inhibitory Concentration) value was measured after incubation for 24 hours by the (Broth dilution) method by Ericsson (Ericsson).
[실시예 3]Example 3
본 발명에 따르는 약제를 병의 정도가 다른 유방염으로 고통받는 40마리의 젖소의 치료에 이용되었다.The agent according to the invention was used for the treatment of 40 cows suffering from mastitis with different degrees of illness.
본 발명에 따르는 약제를 매일 젖을 짜고 연달아 젖통을 가볍게 맛사지를 5-7분 한 후 병든 동물의 젖통 피부에 주입하였다.The medicament according to the invention was milked daily and successively injected into the udder skin of a sick animal after a light massage of 5-7 minutes in succession.
그러므로 본 발명에 따른 약제 치료 후 완전히 치료되어 우유생산이 회복되었다.Therefore, after the drug treatment according to the present invention was completely treated to recover milk production.
(실시예 4)(Example 4)
80마리의 젖소에서 만성적 유방염이 있는 48마리의 동물을 시험목적으로 선택하였다. 임상실험 결과 병든 동물은 다음과 같은 형태의 유방염을 가지고 있었다.Forty-eight animals with chronic mastitis in 80 cows were selected for testing. In clinical trials, sick animals had the following forms of mastitis:
(실시예 5)(Example 5)
1000마리 규모의 젖소농장에서 30마리에 대한 유방염 치료효과를 확인했다.The effect of mastitis on 30 animals was confirmed in 1000 cow farms.
(실시예 6)(Example 6)
시험목적으로 젖소농장에서 유방염 젖소 65마리를 선발하였다. 임상 실험결과 동물의 유방염 형태는 다음과 같다.For the purposes of testing, 65 mammary cows were selected from dairy farms. Following clinical trials, mastitis in animals is as follows.
(실시예 7)(Example 7)
시험목적으로 젖소농장에서 유방염 감염된 젖소를 상대로 경구투여 후 체세포감소효과는 다음과 같다.Somatic reduction effect after oral administration of mastitis-infected cows in dairy farms for
(단위:10,000/ml)(Unit: 10,000 / ml)
(실시예 8)(Example 8)
젖소의 유방염을 유발하는 대표적인 균주인 스타필로스 아우레우스(Staphylococcus aureus)를 사용하여 항균성을 조사하였다. (최초투여균수; 2x105 CFU/ml)Staphylococcus aureus, a representative strain that causes mastitis in cows, was used to investigate the antimicrobial activity. (First dose bacteria; 2x105 CFU / ml)
<표준균주 Staphylococcus aureus ATCC 29213에 대한 항균효과><Antibacterial effect against standard strain Staphylococcus aureus ATCC 29213>
본 발명은 포공영으로부터 항균활성이 높은 엑기스를 추출, 정제하여 임산부와 젖소의 유방염 또는 유선염을 치료하는 발명으로 경제적으로 쉽게 재료를 구할 수 있는 장점이 있다. 또한 본 발명에 의한 포공영 추출물은 물성이 균일하며 ,뛰어나 항균력을 보유하고 있고, 생산단가가 저렴하다. 또한 공정과정이 매우 간단하고, 생산 과정에서 환경오염이 전혀 유발되지 않은 경제적인 추출물의 생산이 가능하다.The present invention has the advantage that it is economically easy to obtain the material to the invention to treat mastitis or mastitis of pregnant women and cows by extracting, purifying the extract with high antimicrobial activity from poongongyoung. In addition, pogongyoung extract according to the present invention has a uniform physical properties, has excellent antimicrobial activity, and low production cost. In addition, the process is very simple, it is possible to produce an economical extract without any environmental pollution in the production process.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020018031A KR20030079185A (en) | 2002-04-02 | 2002-04-02 | Processing method and its Application of Medicine for Treating Mastitis of Expectant and Dairycow Using Dandelion Extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020018031A KR20030079185A (en) | 2002-04-02 | 2002-04-02 | Processing method and its Application of Medicine for Treating Mastitis of Expectant and Dairycow Using Dandelion Extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030079185A true KR20030079185A (en) | 2003-10-10 |
Family
ID=32377562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020018031A KR20030079185A (en) | 2002-04-02 | 2002-04-02 | Processing method and its Application of Medicine for Treating Mastitis of Expectant and Dairycow Using Dandelion Extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20030079185A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109045234A (en) * | 2018-07-25 | 2018-12-21 | 广州格雷特生物科技有限公司 | Containing callicarpa nudiflora Chinese herb medicine additive for milk cow forage and its preparation method and application |
KR20230160028A (en) | 2022-05-16 | 2023-11-23 | 윤병대 | Composition for Somatic Cell Reducer of Milk of Cow Containing Cordycepin with Active Ingredients |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950005739A (en) * | 1993-08-27 | 1995-03-20 | 다쓰노 히로미찌 | Data settlement processor for gas station |
KR960006863A (en) * | 1994-08-16 | 1996-03-22 | 이종균 | Toilet seat with vent |
JPH11246429A (en) * | 1998-03-02 | 1999-09-14 | Momoya Co Ltd | Anti-tumor substance derived from medicinal plant |
KR20010076537A (en) * | 2000-01-26 | 2001-08-16 | 장세순 | Tea tasting of coffee comprising adandelion root powder |
-
2002
- 2002-04-02 KR KR1020020018031A patent/KR20030079185A/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950005739A (en) * | 1993-08-27 | 1995-03-20 | 다쓰노 히로미찌 | Data settlement processor for gas station |
KR960006863A (en) * | 1994-08-16 | 1996-03-22 | 이종균 | Toilet seat with vent |
JPH11246429A (en) * | 1998-03-02 | 1999-09-14 | Momoya Co Ltd | Anti-tumor substance derived from medicinal plant |
KR20010076537A (en) * | 2000-01-26 | 2001-08-16 | 장세순 | Tea tasting of coffee comprising adandelion root powder |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109045234A (en) * | 2018-07-25 | 2018-12-21 | 广州格雷特生物科技有限公司 | Containing callicarpa nudiflora Chinese herb medicine additive for milk cow forage and its preparation method and application |
CN109045234B (en) * | 2018-07-25 | 2021-07-13 | 广州格雷特生物科技有限公司 | Callicarpa nudiflora-containing Chinese herbal medicine feed additive for dairy cows as well as preparation method and application thereof |
KR20230160028A (en) | 2022-05-16 | 2023-11-23 | 윤병대 | Composition for Somatic Cell Reducer of Milk of Cow Containing Cordycepin with Active Ingredients |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0424534B1 (en) | Pharmaceutical preparation for treatment of mastitis in animals and humans | |
CN104208294B (en) | It is a kind of to be used to treat Chinese medicine composition of piglet yellow-white dysentery and preparation method thereof | |
CN113473964B (en) | Propolis liquid extract, preparation and use thereof | |
CN100367989C (en) | Medication for treating disease of alimentary tract of livestock husbandry and birds | |
CN112043817A (en) | Anti-mite composition and application thereof | |
KR20030079185A (en) | Processing method and its Application of Medicine for Treating Mastitis of Expectant and Dairycow Using Dandelion Extract | |
CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
EP2793917B1 (en) | Extract of rhus copallina extract for use as a medicament | |
Kalia et al. | Efficacy of different extracts of propolis against Salmonella enterica serovar Typhimurium: In vitro and in vivo study | |
DE60003453T2 (en) | PHYTOTHERAPEUTIC PREPARATION | |
DE3000521A1 (en) | SUBSTANCE WITH INTERFERON INDUCING ACTIVITY AND METHOD FOR THEIR PRODUCTION | |
CN105582529A (en) | Pharmaceutical composition for treating beriberi | |
CN102697686B (en) | Female care solution and preparation method thereof | |
CN1191066C (en) | Externally-used disinfector | |
CN111990533A (en) | Fermented eucommia ulmoides leaf extract and application thereof in preparation of chicken feed | |
CN101822706B (en) | Gynostemma pellet preparation for preventing subclinical mastitis and preparation method thereof | |
JP4610730B2 (en) | Composition for calcium supplementation | |
RU2303993C1 (en) | Treatment and prophylaxis means applicable for treating young agricultural animals and method for preventing and treating calves for gastrointestinal tract diseases | |
RU2769508C2 (en) | Method for producing combined preparation of animal placenta and phyto-raw material | |
CN1197595C (en) | Chinese medicine preparation for broad-spectrum inflammation relieving, disinfecting, erosion prevention and muscle growing | |
RU2070409C1 (en) | Drug for treatment of mastitis in milking animals | |
RU2364432C1 (en) | Therapy of helminthic invasions | |
CN113082140B (en) | Traditional Chinese medicine compound for treating acute mastitis of dairy cows and preparation method thereof | |
RU2350080C1 (en) | Vegetative molluscicide | |
CN106619767A (en) | Medicine composition for treating dairy cow mastitis as well as preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
E601 | Decision to refuse application | ||
E601 | Decision to refuse application |